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Hepatitis C infection is one of the most common causes
of chronic end-stage liver disease, with its sequelae
decompensated liver cirrhosis and hepatocellular carci-
noma. Both are currently the most important indica-
tions for liver transplantation [1]. Unfortunately, almost
all patients with detectable HCV RNA at the time of
transplantation will have recurrent hepatitis C in their
graft [2]. Although spontaneous clearance can occur
during primary infection [3], under immunosuppressive
therapy this is rather rare [4]. Moreover, recurrent hep-
atitis C after liver transplantation follows a more rapid
course, with the development of liver cirrhosis in
approximately 20-40% of the patients within 5 years [5]
and causing significant graft loss and even death.
Until recently, the only possible treatment was (peg)
interferon-based antiviral therapy. It has been clearly
shown that obtaining sustained virological response
even in the cirrhotic stage is associated with improved
survival by a decrease in both all-cause and liver-related
mortality [6]. In the setting of liver transplantation, the
efficacy is significantly less due to poor tolerance and
the occurrence of (severe) complications [7]. However,
with the introduction of all oral interferon-free direct
antiviral therapy this is past history and hepatitis C in
the setting of liver transplantation can now be treated
as in all other patients, obtaining similar results.
In most countries where liver transplantation is being
performed, hepatitis C after liver transplantation is
being regarded an indication for antiviral therapy with
high priority. Both the European Association for the
Study of the Liver and the American Association for the
Study of Liver Diseases/Infectious Diseases Society of
America advocate the use of direct antiviral agents
(DAAs) after liver transplantation and have designed
specific guidelines for the post-liver transplant setting
[7–9].
With the approval of NS3/4a protease inhibitors
(simeprevir, paritaprevir), NS5a polymerase inhibitors
(daclatasvir, ombitasvir, ledipasvir), NS5b polymerase
inhibitors (sofosbuvir, dasabuvir) and more to come, all
patients after liver transplantation can now be treated,
with almost similar high cure rates as in the non-liver
transplant setting [10–13]. All DAA combinations are
well tolerated, without any severe complication. In the
setting of liver transplantation, important drug–drug
interactions are to be expected, in particular because the
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calcineurin inhibitors tacrolimus and cyclosporin are
the cornerstone of immunosuppressive regimens. How-
ever, with careful monitoring of blood levels and antici-
pating dose adjustments, significant clinical problems
can be prevented. All potential drug–drug interactions
are described on the “Liverpool” website including
recommendations [14].
Although the outcome of hepatitis C treatment has
improved considerably, some challenges still remain; the
most important are the treatment of patients with liver
cirrhosis and decompensated liver cirrhosis, with geno-
type 3 infection and with coexistent renal insufficiency.
The timing of antiviral therapy is for patients in the
liver transplant setting of particular importance: Can it
still be done before or should it always be after trans-
plantation, and what would then be the optimal timing?
When treatment is still feasible before liver transplanta-
tion, preliminary data show that one of five patients
can be delisted [15]; long-term outcome of these
patients is not yet known. Continuing cohort studies
suggest that antiviral therapy might be futile in those
with portal hypertension (as reflected by thrombocy-
topenia), high MELD scores (>14) and/or low albumin
levels [16,17]. In addition, rapid and extensive recurrent
hepatocellular carcinoma might be a specific newly rec-
ognized risk for those previously treated for hepatocel-
lular carcinoma [18].
In the postoperative phase, it is the question whether
the patient should be treated as soon as possible or in a
steady clinical situation, that is after fading of the early-
postoperative risks (surgical complications, infections,
rejection, etc.). However, in particular those patients
with high viral load, genotype 1 infection, females, older
donor age, being treated for cytomegalovirus or for
acute rejection, have a high risk for rapidly progressive
recurrent hepatitis C [19]. But how can we distinguish
high risk in the individual patient?
It might well be that the combination of only two
genetic markers identifies those patients at high risk of
early reduced liver graft survival, and thus could
become an important tool for decision making whether
to treat early or later after liver transplantation. In this
issue of Transplant International, Romagnoli R et al.
[20] describe the role of the expression of HLA variants
and the interleukin-28B (IL28B) C/C genotype
(rs12979860) in the prediction of the outcome of liver
transplantation in HCV recipients. Among 449 patients
with a median follow-up of 10 years, graft survival in
HLA-DRB1*11-positive recipients was significantly
longer than in HLA-DRB1*11-negative recipients; the
difference amounted 17% after 10 years. Graft survival
was also influenced by the IL28B genotype of both
recipient and donor, being better in C/C recipients and
with non-C/C donors; the outcome was significantly
worse in non-C/C recipients transplanted with a C/C
donor. Compared with the HCV recipients exhibiting
all other genetic combinations, patients lacking both
these markers experienced a significant survival disad-
vantage as early as the first post-transplant year, the 1-
year risk of graft loss being increased by 68% (hazard
ratio 1.68). This suggests that both HLA-DRB1*11 and
IL28B genotype should be known before transplanta-
tion: Patients lacking both markers should undergo
antiviral therapy as soon as possible after transplanta-
tion (within 3 months?), whereas others probably can
wait until their clinical course has completely stabilized.
Antiviral therapy of hepatitis C has come to a stage
where almost all patients can be cured. Results in
patients after liver transplantation, in the interferon era
regarded as difficult to treat, are more or less similar.
Some patients are, however, at increased risk of the
development of severe rapidly progressive recurrent
hepatitis C shortly after transplantation. The important
work of Romagnoli et al. indicates that the combined
genotyping of HLA-DRB1*11 and IL28B is necessary to
make a proper decision to treat early (as soon as possi-
ble) or later (after complete stabilization). Although
confirming results should be awaited, liver transplant
centers should already seriously consider to genotype all
HCV patients pretransplant.
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